Top

Published in:

Open Access 01-03-2010

Role of C-Reactive Protein in Contributing to Increased Cardiovascular Risk in Metabolic Syndrome

Authors: Sridevi Devaraj, Simona Valleggi, David Siegel, Ishwarlal Jialal

Published in: Current Atherosclerosis Reports | Issue 2/2010

Abstract

Metabolic syndrome is associated with increased propensity for diabetes and cardiovascular disease. Low-grade inflammation is characteristic of metabolic syndrome. C-reactive protein, the best characterized biomarker of inflammation, is also an independent predictor of future cardiovascular events. This review outlines the role of high-sensitivity C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome by inducing endothelial cell dysfunction and activating monocytes.

Reaven GM: The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 2005, 25:391–406.CrossRefPubMed

Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 2005, 365:1415–1428.CrossRefPubMed

Haffner S, Cassells HB: Metabolic syndrome—a new risk factor of coronary heart disease? Diabetes Obes Metab 2003, 5:359–370.CrossRefPubMed

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III. JAMA 2001, 285:2486–2497.CrossRef

Ford ES: Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005, 28:2745–2749.CrossRefPubMed

Lakka HM, Laaksonen DE, Lakka TA, et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709–2716.CrossRefPubMed

Alexander CM, Landsman PB, Teutsch SM, Haffner SM: Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003, 52:1210–1214.CrossRefPubMed

Devaraj S, Rosenson RS, Jialal I: Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am 2004, 33:431–453.CrossRefPubMed

Hanson RL, Imperatore G, Bennett PH, Knowler WC: Components of the “metabolic syndrome” and incidence of type 2 diabetes. Diabetes 2002, 51:3120–3127.CrossRefPubMed

10.

Freeman D, Norrie J, Sattar N, et al.: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103:357–362.PubMed

11.

Assmann G, Nofer JR, Schulte H: Cardiovascular risk assessment in metabolic syndrome: view from PROCAM. Endocrinol Metab Clin North Am 2004, 33:377–392.CrossRefPubMed

12.

Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836–843.CrossRefPubMed

13.

Ridker PM, Glynn RJ, Hennekens CH: C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998, 97:2007–2011.PubMed

14.

Ridker PM, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003,107:391–397.CrossRefPubMed

15.

Ballantyne CM, Hoogeveen RC, Bang H, et al.: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005, 165:2479–2484.CrossRefPubMed

16.

Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279:1615–1622.CrossRefPubMed

17.

Koenig W, Khuseyinova N, Baumert J, Meisinger C: Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: results from the MONICA/KORA Augsburg Cohort Study, 1984–1998. Clin Chem 2008, 54:335–342.CrossRefPubMed

18.

Eiriksdottir G, Aspelund T, Bjarnadottir K, et al.: Apolipoprotein E genotype and statins affect CRP levels through independent and different mechanisms: AGES-Reykjavik Study. Atherosclerosis 2006, 186:222–224.CrossRefPubMed

19.

Yudkin JS, Juhan-Vague I, Hawe E, et al.; The HIFMECH Study Group: Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism 2004, 53:852–857.CrossRefPubMed

20.

Festa A, D’Agostino R Jr, Howard G, et al.: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102:42–47.PubMed

21.

Ford ES: The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis. 2003, 168:351–358.CrossRefPubMed

22.

Sattar N, Gaw A, Scherbakova O, et al.: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003, 108:414–419.CrossRefPubMed

23.

Suzuki T, Katz R, Jenny NS, et al.: Metabolic syndrome, inflammation, and incident heart failure in the elderly: the Cardiovascular Health Study. Circ Heart Fail 2008, 1:242–248.CrossRefPubMed

24.

Malik S, Wong ND, Franklin SS, et al.: Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004, 110:1245–1250.CrossRefPubMed

25.

Pischon T, Hu FB, Rexrode KM, et al.: Inflammation, the metabolic syndrome, and risk of coronary heart disease in women and men. Atherosclerosis 2008, 197:392–399.CrossRefPubMed

26.

Takeno M, Yasuda S, Otsuka Y, et al.: Impact of metabolic syndrome on the long-term survival of patients with acute myocardial infarction: potential association with C-reactive protein. Circ J 2008, 72:415–419.CrossRefPubMed

27.

Zuliani G, Volpato S, Galvani M, et al.: Elevated C-reactive protein levels and metabolic syndrome in the elderly: the role of central obesity data from the InChianti study. Atherosclerosis 2009, 203:626–632.CrossRefPubMed

28.

Ridker PM, Pare G, Parker A, et al.: Loci related to metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women’s Genome Health Study. Am J Hum Genet 2008, 82:1185–1192.CrossRefPubMed

29.

Meier-Ewert HK, Ridker PM, Rifai N, et al.: Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 2001, 47:426–430.PubMed

30.

Ockene IS, Matthews CE, Rifai N, et al.: Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001, 47:444–450.PubMed

31.

Ridker PM, Wilson PW, Grundy SM: Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004, 109:2818–2825.CrossRefPubMed

32.

Devaraj S, Singh U, Jialal I: Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol 2009, 20:182–189.CrossRefPubMed

33.

Al-Qaisi M, Kharbanda RK, Mittal TK, et al.: Measurement of endothelial function and its clinical utility for cardiovascular risk. Vasc Health Risk Manag 2008, 4:647–652.PubMed

34.

Lamon BD, Hajjar DP: Inflammation at the molecular interface of atherogenesis: an anthropological journey. Am J Pathol 2008, 173:1253–1264.CrossRefPubMed

35.

Bakker W, Eringa EC, Sipkema P, et al.: Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. Cell Tissue Res 2009, 335:165–189.CrossRefPubMed

36.

Corretti MC, Anderson TJ, Benjamin EJ, et al.; International Brachial Artery Reactivity Task Force: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002, 39:257–265.CrossRefPubMed

37.

Vita JA, Keaney JF Jr: Endothelial function: a barometer for cardiovascular risk? Circulation 2002,106:640–642.CrossRefPubMed

38.

Caballero AE: Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res 2003, 11:1278–1289.CrossRefPubMed

39.

Shankar SS, Steinberg HO: Obesity and endothelial dysfunction. Semin Vasc Med 2005, 5:56–64.CrossRefPubMed

40.

Hsueh WA, Quinones MJ: Role of endothelial dysfunction in insulin resistance. Am J Cardiol 2003, 92:10J–17J.CrossRefPubMed

41.

Suzuki T, Hirata K, Elkind MS, et al.: Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: the Northern Manhattan Study (NOMAs). Am Heart J 2008, 156:405–410.CrossRefPubMed

42.

Hamburg NM, Larson MG, Vita JA, et al.: Metabolic syndrome, insulin resistance, and brachial artery vasodilator function in Framingham Offspring participants without clinical evidence of cardiovascular disease. Am J Cardiol 2008, 101:82–88.CrossRefPubMed

43.

Melikian N, Chowienczyk P, MacCarthy PA, et al.: Determinants of endothelial function in asymptomatic subjects with and without the metabolic syndrome. Atherosclerosis 2008, 197:375–382.CrossRefPubMed

44.

Rodriguez CJ, Miyake Y, Grahame-Clarke C, et al.: Relation of plasma glucose and endothelial function in a population-based multiethnic sample of subjects without diabetes mellitus. Am J Cardiol 2005, 96:1273–1277.CrossRefPubMed

45.

Brook RD, Bard RL, Rubenfire M, et al.: Usefulness of visceral obesity (waist/hip ratio) in predicting vascular endothelial function in healthy overweight adults. Am J Cardiol 2001, 88:1264–1269.CrossRefPubMed

46.

Wheatcroft SB, Shah AM, Li JM, et al.: Preserved glucoregulation but attenuation of the vascular actions of insulin in mice heterozygous for knockout of the insulin receptor. Diabetes 2004, 53:2645–2652.CrossRefPubMed

47.

Steinberg HO, Chaker H, Leaming R, et al.: Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996, 97:2601–2610.CrossRefPubMed

48.

Teoh H, Quan A, Lovren F, et al.: Impaired endothelial function in C-reactive protein overexpressing mice. Atherosclerosis 2008, 201:318–325.CrossRefPubMed

49.

Grad E, Golomb M, Mor-Yosef I, et al.: Transgenic expression of human C-reactive protein suppresses endothelial nitric oxide synthase expression and bioactivity after vascular injury. Am J Physiol Heart Circ Physiol 2007, 293:H489–H495.CrossRefPubMed

50.

Venugopal SK, Devaraj S, Jialal I: C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation 2003, 108:1676–1678.CrossRefPubMed

51.

Schwartz R, Osborne-Lawrence S, Hahner L, et al.: C-reactive protein downregulates endothelial NO synthase and attenuates reendothelialization in vivo in mice. Circ Res 2007, 100:1452–1459.CrossRefPubMed

52.

Fichtlscherer S, Breuer S, Schächinger V, et al.: C-reactive protein levels determine systemic nitric oxide bioavailability in patients with coronary artery disease. Eur Heart J 2004, 25:1412–1428.CrossRefPubMed

53.

Fichtlscherer S, Rosenberger G, Walter DH, et al.: Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000,102:1000–1006.PubMed

54.

Cleland SJ, Sattar N, Petrie JR, et al.: Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci 2000, 98:531–535.CrossRefPubMed

55.

Venugopal SK, Devaraj S, Yuhanna I, et al.: Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002, 106:1439–1441.CrossRefPubMed

56.

Verma S, Wang CH, Li SH, et al.: A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002, 106:913–919.CrossRefPubMed

57.

• Singh U, Devaraj S, Vasquez-Vivar J, Jialal I: C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. J Mol Cell Cardiol 2007, 43:780–791. This study describes mechanisms by which CRP increases oxidative stress, resulting in uncoupling of eNOS and reduced eNOS bioactivity, possibly explaining its role in causing ED.CrossRefPubMed

58.

•• Guan H, Wang P, Rutai H, et al.: Adeno-associated virus-mediated human C-reactive protein gene delivery causes endothelial dysfunction and hypertension in rats. Clin Chem 2009, 55:274–284. This study is an in vivo demonstration that administration of CRP results in ED and hypertension.CrossRefPubMed

59.

Devaraj S, Xu DY, Jialal I: C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003,107:398–404.CrossRefPubMed

60.

Singh U, Devaraj S, Jialal I: C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arterioscler Thromb Vasc Biol 2005, 25:2216–2221.CrossRefPubMed

61.

Nakakuki T, Ito M, Iwasaki H, et al.: Rho/Rho-kinase pathway contributes to C-reactive protein-induced plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol 2005, 25:2088–2093.CrossRefPubMed

62.

Ingelsson E, Hulthe J, Lind L: Inflammatory markers in relation to insulin resistance and the metabolic syndrome. Eur J Clin Invest 2008, 38:502–509.CrossRefPubMed

63.

Conen D, Rexrode KM, Creager MA, et al.: Metabolic syndrome, inflammation and risk of symptomatic PAD in women. Circulation 2009, 120:1041–1047.CrossRefPubMed

64.

Kressel G, Trunz B, Bub A, et al.: Systematic and vascular markers of inflammation in relation to metabolic syndrome and insulin resistance in adults with elevated atherosclerosis risk. Atherosclerosis 2009, 202:263–271.CrossRefPubMed

65.

Rosso LG, Benitez MB, Fornari MC, et al.: Alterations in cell adhesion molecules and other biomarkers of cardiovascular disease in patients with MetS. Atherosclerosis 2008, 199:415–423.CrossRef

66.

Devaraj S, Davis B, Simon SI, Jialal I: CRP promotes monocyte-endothelial cell adhesion via Fcgamma receptors in human aortic endothelial cells under static and shear flow conditions. Am J Physiol Heart Circ Physiol 2006, 291:H1170–H1176.CrossRefPubMed

67.

Cermak J, Key NS, Bach RR, et al.: C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993, 82:513–520.PubMed

68.

Devaraj S, Dasu MR, Singh U, et al.: C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis 2009, 203:67–74.CrossRefPubMed

69.

Han KH, Hong KH, Park JH, et al.: C-reactive protein promotes monocyte chemoattractant protein-1 mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 2004, 109:2566–2571.CrossRefPubMed

70.

Williams TN, Zhang CX, Game BA, et al.: C-reactive protein stimulates MMP-1 expression in U937 histiocytes through Fc[gamma]RII and extracellular signal-regulated kinase pathway: an implication of CRP involvement in plaque destabilization. Arterioscler Thromb Vasc Biol 2004, 24:61–66.CrossRefPubMed

71.

Woollard KJ, Fisch C, Newby R, et al.: C-reactive protein mediates CD11b expression in monocytes through the non-receptor tyrosine kinase, Syk, and calcium mobilization but not through cytosolic peroxides. Inflamm Res 2005, 54:485–492.CrossRefPubMed

72.

Chang MK, Binder CJ, Torzewski M, et al.: C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A 2002, 99:13043–13048.CrossRefPubMed

73.

Wang X, Liao D, Bharadwaj U, et al.: C-reactive protein inhibits cholesterol efflux from human macrophage-derived foam cells. Arterioscler Thromb Vasc Biol 2008, 28:519–526.CrossRefPubMed

74.

• Singh U, Dasu MR, Yancey PG, et al.: Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats. J Lipid Res 2008, 49:1015–1023. In this study, the authors demonstrate in vivo that CRP induces oxidative stress and promotes cholesterol ester accumulation and foam cell formation.CrossRefPubMed

75.

Singh U, Devaraj S, Jialal I: C-Reactive protein stimulates myeloperoxidase release from polymorphonuclear cells and monocytes. Clin Chem 2009, 55:361–364.CrossRefPubMed

76.

Han KH, Hong KH, Park JH, et al.: C-reactive protein promotes monocyte chemoattractant protein-1—mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 2004,109:2566–2571.CrossRefPubMed

77.

Esposito K, Pontillo A, Giugliano F, et al.: Association of low interleukin-10 levels with the metabolic syndrome in obese women. J Clin Endocrinol Metab 2003, 88:1055–1058.CrossRefPubMed

78.

Singh U, Devaraj S, Dasu MR, et al.: C-reactive protein decreases interleukin-10 secretion in activated human monocyte-derived macrophages via inhibition of cyclic AMP production. Arterioscler Thromb Vasc Biol 2006, 26:2469–2475.CrossRefPubMed

79.

Bisoendial RJ, Birjmohun RS, Akdim F, et al.: C-reactive protein elicits white blood cell activation in humans. Am J Med 2009, 122:582.e1–9.CrossRef

80.

Fortuño A, San José G, Moreno MU, et al.: Phagocytic NADPH oxidase overactivity underlies oxidative stress in metabolic syndrome. Diabetes 2006, 55:209–215.CrossRefPubMed

81.

Keaney JF Jr, Larson MG, Vasan RS, et al.: Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003, 23:434–439.CrossRefPubMed

82.

Kobayashi S, Inoue N, Ohashi Y, et al.: Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of CRP. Arterioscler Thromb Vasc Biol 2003, 23:1398–1404.CrossRefPubMed

83.

Ehara S, Ueda M, Naruko T: Elevated levels of oxidized low-density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001, 103:1955–1960.PubMed

84.

Holvoet P, Kritchevsky SB, Tracy RP, et al.: The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes 2004, 53:1068–1073.CrossRefPubMed

85.

Diamant M, Nieuwland R, Pablo RF, et al.: Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002, 106:2442–2447.CrossRefPubMed

86.

Goncalves FM, Jacob-Ferreira AL, Gomes VA, et al.: Increased circulating levels of MMP-8, MMP-9 and pro-inflammatory markers in patients with metabolic syndrome. Clin Chim Acta 2009, 403:173–177.CrossRefPubMed

87.

Barnes PJ, Karin M: Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997, 336:1066–1071.CrossRefPubMed

88.

Ghanim H, Aljada A, Hofmeyer D, et al.: Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 2004, 110:1564–1571.CrossRefPubMed

89.

Devaraj S, Chan E, Jialal I: Direct demonstration of an anti-inflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab 2006, 91:4489–4496.CrossRefPubMed

90.

•• Ridker PM, Danielson E, Fonseca F, et al.: Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med 2008, 359:2195–2207. This primary prevention trial with rosuvastatin showed a significant 37% reduction in cardiovascular events. Although rosuvastatin reduced LDL cholesterol by 50%, the reduction in cardiovascular events in JUPITER was almost twice that predicted based on LDL cholesterol reduction, and CRP levels were significantly reduced by 37%. Most importantly, in those with no risk factors except a high CRP, there was an equivalent benefit, supporting the hypothesis that CRP may mediate atherothrombosis.CrossRefPubMed

91.

Jialal I, Devaraj S: Statin therapy for the metabolic syndrome. The evidence base. Met Syndr Relat Disord 2009, 7:393–395.CrossRef

Title: Role of C-Reactive Protein in Contributing to Increased Cardiovascular Risk in Metabolic Syndrome
Authors: Sridevi Devaraj
Simona Valleggi
David Siegel
Ishwarlal Jialal
Publication date: 01-03-2010
Publisher: Current Science Inc.
Published in: Current Atherosclerosis Reports / Issue 2/2010
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-010-0098-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Depression and Coronary Heart Disease

Lp-PLA2 as a Marker of Cardiovascular Diseases

The Spectrum of Atherosclerotic Coronary Artery Disease in HIV Patients

Coronary Heart Disease and Body Fat Distribution

Does Statin Therapy Affect the Progression of Atherosclerosis Measured by a Coronary Calcium Score?

A Cardiologist’s View of Hypoglycemia

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials